Wednesday, March 9

7:30am-5:00pm Grant Review Committee Meeting (by invitation)........Milken Institute, 730 15th St NW, 2nd floor
11:45-5:30pm Melanoma Patients, Advocates & Foundations Forum..........................J.W. Marriott, Salon II & III
4:00-8:00pm Retreat Registration open ................................................................. Foyer of Penn Avenue Terrace
6:00-7:30pm Opening Reception ........................................................................ Penn Avenue Terrace

Thursday, March 10

6:30am-6:00pm Registration ................................................................................. Foyer of Salon III & IV
7:00-8:15am General Breakfast ........................................................................... Salon II
7:00-8:15am Young Investigators Breakfast (by invitation) ................................... Salon I
8:30-8:45am Opening Remarks Day 1................................................................. Salon III & IV
Michael Kaplan, MRA President & CEO
Keith Tolley, Patient Advocate
J.B. Ward, Patient Advocate
Marc Hurlbert, MRA Chief Science Officer

8:45-9:15am Lecture
Jason Luke, University of Pittsburgh – Integrating clinical and genomic observations to advance combination therapies in melanoma

9:15-11:40am Session 1: Novel treatment strategies for melanoma
Chair: C. Daniela Robles-Espinoza, National Autonomous University of Mexico

9:15-9:40am Rhoda Alani, Boston University:
The CoREST repressor complex as a mediator of phenotype switching and therapy resistance in melanoma

9:40-10:05am Jiyue Zhu, Washington State University: Telomere homeostasis in melanoma

10:05-10:30am Break

10:30-10:55am Thomas Graeber, University of California, Los Angeles: Plasticity of extrachromosomal and intrachromosomal BRAF amplifications in overcoming targeted therapy dosage challenges

10:55-11:15am Daniela De Zio, Danish Cancer Society Research Center & University of Copenhagen:
The tumor suppressor role of Ambra1 in melanoma

11:15-11:40am Adam Hurlstone, University of Manchester: Fat uptake into and fat storage in melanoma cells promotes melanoma formation but are actionable targets
11:40am-11:55am  Transition to lunch

11:55am-1:20pm  Networking Lunch and General Roundtables ................................................................. Salon I & II

1. Acral + mucosal patient registry (salon H/J)  11. Mentoring / mentorship
2. Biomarkers  12. Metastasis and tumor dormancy
5. Diversity  15. Prevention
7. Genomics  17. Tumor microenvironment
8. Intrallesional therapies  18. Vaccines
10. Melanoma model systems  20. Women in melanoma research and care

1:20-1:25pm  Transition to general session room (Salon III & IV)

1:30-3:00pm  Session 2: Next generation immunotherapies and addressing irAEs .......... Salon III & IV

Chair: Joan Levy, Melanoma Research Alliance

1:30-1:55pm  David Gerber, UT Southwestern: Trouble in paradise? Immunotherapy selection, and toxicities

1:55-2:15pm  Ken Hsu, University of Virginia: Functional reporters of T cell metabolism for immunotherapy applications

2:15-2:35pm  Simon Heidegger, Munich Technical University: Tumor-derived extracellular vesicles as personalized anti-tumor agents in melanoma

2:35-3:00pm  Michal Lotem, Hadassah Medical Organization: Spliced immune receptors for immune regulation and melanoma immunotherapy

3:00-3:30pm  Break

3:30-4:30pm  Session 3: Special Focus – Highlighting MRA Young Investigator Awardees

Chair: Kim Blenman, Yale University

3:30-3:40pm  Rachel Vogel, University of Minnesota: Effectiveness of a UVR-sensor wearable device intervention to improve sun behaviors and reduce sunburns in melanoma survivors

3:40-3:50pm  Veronica Rotemberg, Memorial Sloan Kettering Cancer Center: Factors that influence automated melanoma detection

3:50-4:00pm  Ed Stites, Salk Institute: Computational analyses of RAS/RAF pathway signaling

4:00-4:10pm  Ashley Laughney, Joan & Sanford I. Weill Medical College of Cornell University: Single cell analyses reveal an unexpected link between epigenetic dysregulation and chromosomal instability in uveal melanoma progression

4:10-4:20pm  Russell Jenkins, Massachusetts General Hospital: Targeting TBK1 to overcome resistance to cancer immunotherapy
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:25-4:30pm</td>
<td>Closing Remarks Day 1</td>
<td>Rachel Fischer, MRA Senior Scientific Program and Registry Manager</td>
</tr>
<tr>
<td>4:45-6:15pm</td>
<td>Poster Session I: Features Dermatology Fellow, Young Investigator, Pilot Awardees, and Sponsors</td>
<td>Light refreshments, all retreat attendees encouraged to attend</td>
</tr>
</tbody>
</table>

*Dinner on Your Own: Explore DC, meet up with friends, or take it easy!*

### Friday, March 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30-10:00am</td>
<td>Registration open</td>
<td>Foyer of Salon III &amp; IV</td>
</tr>
<tr>
<td>7:00-8:50am</td>
<td>General Breakfast</td>
<td>Salon II</td>
</tr>
<tr>
<td>7:20-8:50am</td>
<td>Poster Session II: Features Young Investigator Awardees</td>
<td>Salon I &amp; II</td>
</tr>
<tr>
<td>7:30-8:50am</td>
<td>Industry Roundtable Breakfast (by invitation)</td>
<td>Willard Intercontinental, Willard Room</td>
</tr>
<tr>
<td>9:00-9:05am</td>
<td>Opening Remarks Day 2</td>
<td>Salon III &amp; IV</td>
</tr>
<tr>
<td></td>
<td>Joan Levy, Senior Director, Special Scientific Projects</td>
<td></td>
</tr>
<tr>
<td>9:05-9:35am</td>
<td>Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Laurence Zitvogel, Institut Gustave Roussy: Impact of the intestinal microbiota on the clinical efficacy of immune checkpoint blockade</td>
<td></td>
</tr>
<tr>
<td>9:35-10:20am</td>
<td>Session 4: Improving risk assessment &amp; anti-tumor immunity in melanoma</td>
<td>Chair: Shaheen Khan, University of Texas Southwestern</td>
</tr>
<tr>
<td></td>
<td>Maria Wei, University of California, San Francisco: Applying artificial intelligence to melanoma screening and detection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leonard Zon, Harvard Medical School: Craters on the melanoma surface serve as hubs for CD8+ T cells</td>
<td></td>
</tr>
<tr>
<td>10:20-10:40am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:40-11:30am</td>
<td>Session 5: Understanding therapeutic resistance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Roberto Tinoco, University of California Irvine</td>
<td></td>
</tr>
<tr>
<td>10:40-11:05am</td>
<td>Roger Lo, University of California, Los Angeles: Targeting adaptive immune resistance by degrading tumor cell-surface PD-L1 to promote anti-melanoma therapeutic efficacy</td>
<td></td>
</tr>
<tr>
<td>11:05-11:30am</td>
<td>Jean-Christophe Marine, VIB: Charting dynamics &amp; functional maps of the evolving melanoma ecosystem</td>
<td></td>
</tr>
</tbody>
</table>
11:30am-12:30pm  Panel Discussion: Treating melanoma in 2022: An evolving landscape
Moderator: Jonathan Simons (MRA Board Member)
Panelists:
• Rodabe Amaria, University of Texas MD Anderson Cancer Center
• Michael Atkins, Georgetown University
• Evan Lipson, Johns Hopkins University
• Marlana Orloff, Thomas Jefferson University

12:30pm-12:45pm  Closing Remarks
Marc Hurlbert and Rachel Fischer

12:45-1:45 pm  Lunch and Departures .................................................................Salon II
11:30-11:45am  Registration & Check in*

11:45-1:00pm  Networking Roundtables with Lunch*

1:00-1:10pm  Welcome Remarks
*Michael Kaplan – President & CEO, Melanoma Research Alliance

1:10-1:45pm  Biomarkers: Lighting the Way
From diagnosis to treatment selection, biomarker tests are increasingly being used to inform the care we receive. Learn what exists and how they’re used.
David Polsky, MD, PhD - New York University Langone Health

1:45-2:45pm  One Step at a Time: A Melanoma Journey
While no two melanoma journeys are exactly alike, similarities exist. Get tips and insight as this panel takes us through a hypothetical patient journey.
Danielle Bello, MD - Memorial Sloan Kettering Cancer Center
Hensin Tsao, MD, PhD - Massachusetts General Hospital
Rodabe Amaria, MD - The University of Texas MD Anderson Cancer Center

2:45-3:00pm  Break

3:00-3:55pm  Step-by-Step: Living with Melanoma: A Panel Conversation
Hear from this diverse panel of people who have been impacted by melanoma.
Amy Jardon - Melanoma Advocate
J.B. Ward - Melanoma Advocate
Christine Garrison - Vice President, Melanoma Action Coalition
Cody Barnett - Director of Communications & Patient Engagement, MRA

3:55 - 4:30pm  On the Horizon: Emerging Therapies to Watch
The melanoma research landscape is advancing rapidly, with many clinical trials reporting positive results. Learn how these results are being translated into the clinic.
Hussein Tawbi, MD, PhD - The University of Texas MD Anderson Cancer Center

4:30 - 5:25 pm  Staying on the Path: Prevention for the Melanoma Community
We all know the importance sun safety and prevention, but what does that really look like for people in the melanoma community? Get your questions ready for this interactive panel discussion.
Susan Swetter, MD - Stanford University
Rachel Vogel, PhD - University of Minnesota
Maria Wei, MD, PhD - University of California San Francisco
Tracy Callahan - President & CEO, Polka Dot Mama Melanoma Foundation

5:25 - 5:30pm  Closing & Wrap-up